Oncolytics Biotech Completes Initial Scale Up of Manufacturing Process for REOLYSIN® to Commercial Scale
News Oct 15, 2008
Oncolytics Biotech Inc. has announced that it has successfully completed initial scale up of its manufacturing process for REOLYSIN® to commercial scale.
The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.
"Our existing manufacturing capacity at 40 litres allows us to support future pivotal clinical studies with REOLYSIN®," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "Using this process, a 100-litre manufacturing facility has the potential to produce more than one million doses a year for intravenous use."
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE